Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00.

For the remainder of the year, Puma aims for a gradual sales recovery and benefits from its NextLevel restructuring plan.

The world's leading climate coalition for the banking sector is canvassing members over changes to its rules, its chair told ...

Siegmann Brings Extensive Industry & Investment Experience to StifelST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today appointed Jonathan Siegmann as Managing ...

Stifel Financial on Thursday said it has been ordered to pay $132 million connection with allegations regarding investment recommendations. The Financial Industry Regulatory Authority, a U.S.

M&T Bank Corp grew its position in shares of Masimo Co. (NASDAQ:MASI – Free Report) by 4.9% in the 4th quarter, ...

Bank of New York Mellon Corp cut its holdings in shares of Ambarella, Inc. (NASDAQ:AMBA – Free Report) by 4.1% in the 4th ...

A Finra arbitration panel has ordered Stifel Financial Corp. to pay about $132 million in damages for allegedly misleading ...

A Finra panel ruled the firm's conduct overconcentrated the family in structured notes and limited industries.

Discover why Jefferies Financial Group is a strong buy at ~$55, with improving efficiency, diverse revenue streams, and ...

Investors are selling shares of financial companies as they weigh the impacts of tariffs and slower economic growth.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...